Search results
Texas Company's Mission to Cure Macular Degeneration Blindness
The Joplin Globe· 3 days agoTwenty Million people in America (12% of the population over 40) have Macular Degeneration and Two...
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
Newswise· 23 hours agoTwo treatments for retinal diseases, invented by Neena Haider, PhD, that currently are in clinical trials run by Ocugen, represent a conceptually broad, new approach that ...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 2 days agoThe paper-based KeepSight Journal from the International Macular and Retinal Foundation, Genentech's...
Home vision tests offer limited diagnostic accuracy for neovascular AMD
Medical Xpress· 4 days agoNo home-monitoring vision test has the diagnostic accuracy of hospital eye service follow-up clinics...
Scientists find potential treatment target for leading cause of blindness
Investing.com· 2 days agoNew Delhi, May 2 (IANS) US scientists have found answers to why treatment for neovascular...
...Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry...
Benzinga· 3 days agoLuxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the
Vision-Language Models for Feature Detection of Macular Diseases on Optical Coherence Tomography
Journal of the American Medical Association· 2 days agoThis cross-sectional study evaluates the performance of a vision-language model in performing ophthalmologic tasks related to interpretation of optical coherence tomography scans.
Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema
Digital Journal· 4 days agoHeadquartered in Menlo Park, California, Emmecell is also the parent company...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WTNH-TV New Haven· 4 days agoEB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks· 2 days agoRegeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.